Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
503
Total raised
£3.8B
disclosed amounts
This month
£36.9M
raised so far
The London-based start-up has closed the first tranche of an oversubscribed pre-seed round backed by angel and institutional investors.
"This funding will allow us to expand AirTrack’s capabilities and bring cleaner air to more communities globally. We are committed to improving public health and empowering individuals to take control of their environment for better overall well-being."
The funding round includes backing from Lifted Ventures and supports the creation of a high-throughput semen analyser.
"This funding represents a pivotal moment for Dyneval. By expanding the capabilities of the Dynescan, we’re enabling experts to gain precise insights that improve reproductive outcomes for livestock, with transformative potential for human fertility research."
The seed round was backed by Firstminute Capital, 2100 Ventures, and Vento to accelerate product development and commercial growth.
"The veterinary industry desperately needs modern software solutions that can help practices handle growing demand while reducing administrative burden on overworked staff. We’ve built Lupa from the ground up to be AI-native, making it dramatically more efficient and easier to use than legacy systems that are holding practices back. Our early results show that practices can save significant time on administration while providing better care."
Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
"The widespread success of GLP-1s for weight management has certainly changed the management landscape in obesity, but high discontinuation rates mean that they represent an imperfect solution to a complex issue. With the funding secured in this round, we will be able to significantly progress our path to clinic for DBL’s lead candidates which target greater fat vs muscle loss and provide a much-required alternative to GLP-1s for the majority of users forced to discontinue GLP-1s due to intolerance."
